8TUD image
Deposition Date 2023-08-16
Release Date 2024-06-26
Last Version Date 2024-10-23
Entry Detail
PDB ID:
8TUD
Keywords:
Title:
IgG1 Fc Heterodimer combYSelect2
Biological Source:
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.00 Å
R-Value Free:
0.28
R-Value Work:
0.19
R-Value Observed:
0.20
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Immunoglobulin gamma-1 heavy chain
Mutations:D399Y, K447S
Chain IDs:A
Chain Length:232
Number of Molecules:1
Biological Source:Homo sapiens x Mus musculus hybrid cell line
Polymer Type:polypeptide(L)
Molecule:Immunoglobulin gamma-1 heavy chain
Mutations:K409S, T411Y
Chain IDs:B
Chain Length:232
Number of Molecules:1
Biological Source:Homo sapiens x Mus musculus hybrid cell line
Primary Citation
Combinatorially restricted computational design of protein-protein interfaces to produce IgG heterodimers.
Sci Adv 10 eadk8157 eadk8157 (2024)
PMID: 38598628 DOI: 10.1126/sciadv.adk8157

Abstact

Redesigning protein-protein interfaces is an important tool for developing therapeutic strategies. Interfaces can be redesigned by in silico screening, which allows for efficient sampling of a large protein space before experimental validation. However, computational costs limit the number of combinations that can be reasonably sampled. Here, we present combinatorial tyrosine (Y)/serine (S) selection (combYSelect), a computational approach combining in silico determination of the change in binding free energy (ΔΔG) of an interface with a highly restricted library composed of just two amino acids, tyrosine and serine. We used combYSelect to design two immunoglobulin G (IgG) heterodimers-combYSelect1 (L368S/D399Y-K409S/T411Y) and combYSelect2 (D399Y/K447S-K409S/T411Y)-that exhibit near-optimal heterodimerization, without affecting IgG stability or function. We solved the crystal structures of these heterodimers and found that dynamic π-stacking interactions and polar contacts drive preferential heterodimeric interactions. Finally, we demonstrated the utility of our combYSelect heterodimers by engineering both a bispecific antibody and a cytokine trap for two unique therapeutic applications.

Legend

Protein

Chemical

Disease

Primary Citation of related structures